Clinical Trials Browser

Phase 1/2 × Idarubicin × 90 days × Clear all

NCT03214562 2026-03-05

Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia

Phase 1/2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute